BPG is committed to discovery and dissemination of knowledge
Home / Archive / Volume 11, Issue 11
  • This Article
Academic Content and Language Evaluation of This Article
CrossCheck and Google Search of This Article
Academic Rules and Norms of This Article
Citation of this article
Corresponding Author of This Article
Research Domain of This Article
Article-Type of This Article
Open-Access Policy of This Article
Times Cited Counts in Google of This Article
Number of Hits and Downloads for This Article
  • Total Article Views (12184)
All Articles published online
The chart showing PDF series, WORD series, HTML series, Figures (1-3) series, Tables (1-6) series.
Item 
Count 
PDF615
WORD256
HTML5316
Figures (1-3)626
Tables (1-6)491
 Sum=7304
Featured Article
The chart showing Browse series, Download series.
Item 
Count 
Browse609
Download1377
 Sum=1986
Publishing Process of This Article
The chart showing Browse series, Download series.
Item 
Count 
Browse1017
Download1877
 Sum=2894
Nov 26, 2019 (publication date) through Oct 22, 2025
Times Cited of This Article
Journal Information of This Article
Publication Name
World Journal of Stem Cells
ISSN
1948-0210
Publisher of This Article
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Review
Copyright ©The Author(s) 2019.
World J Stem Cells. Nov 26, 2019; 11(11): 920-936
Published online Nov 26, 2019. doi: 10.4252/wjsc.v11.i11.920
Table 1 Negative correlation between combined expression of cancer stem cell markers CD133, CD44 and CD166 and epigenetic writers
Family/gene symbolEpidrug/chemical probeClinical trials for CRCResults/statusZ-scoreP value
DNA methyltransferases5-azacytidine (Vidaza)1Early Phase I to phase II[63,64]No OR[63,65]
5-aza-2’-désoxycytidine (Decitabine)1Phase I to phase II[66-68]No OR[66]; beneficial with Panitumumab[68]
EGCG (Green tea extract)Preclinical spheroid-derived cancer stem cell xenograft models[69]Sensitization to chemotherapy
ZebularinePreclinical xenografts[70]Anticancer activity
RG108, Procainamide2
DNMT3A, DNMT3B, DNMT3L-2.788/-4.848/-4.321< 0.005
Activating Lysine methyltransferases
SETD6vp22-RelA302-3163[71]-4.6413.47E-06
SETD1A-4.3751.212E-05
Repressive Lysine methyltransferases
SMYD5--4.5146.371E-06
EHMT2UNC02243, UNC06423, BIX-012943-4.3221.545E-05
SETDB2--3.60.0003176
PRDM13--3.442< 0.005
SUV39H1, SUV39H2Chaetocin3-3.422/-2.9340.0006216
PRDM12--3.0890.00201
EZH1UNC19993-2.7870.005314
EZH2CPI-12052,4, EPZ-6438 (Tazemetostat)2, DZNep2, UNC19993-2.4950.01259
Arginine methyltransferases
CARM1MS0493, SGC20853, TP-0643[72]-3.8120.0001381
PRMT1MS0233[72]-3.6590.0002534
PRMT6MS0233, MS049c, EPZ0204113[72], 6′-methyleneamine sinefungin3[73]-3.5210.0004301
Histone acetylation
KAT2ACPTH23[74], γ-butyrolactone3 (MB-3)[75]-4.6832.823E-06
NAA10, NAA16, NAA20, NAA38, NAA40--4.335/-3.255/-3.786/-3.801/-2.665< 0.01
NAT8, NAT9--2.573/-3.995< 0.01
NCOA5, NCOA6--3.238/-3.112< 0.002
Histone phosphorylation
BAZ1B--2.3740.01758
Histone glycosylation
OGT--3.1720.001512
1Approved for the treatment of other diseases;
2Used in clinical trials for other diseases;
3Not yet used in clinical trials;
4Activator. CRC: Colorectal cancer; OR: Objective response.
Full Size Table
Table 2 Negative correlation between combined expression of cancer stem cell markers CD133, CD44 and CD166 and epigenetic erasers
Family/gene symbolEpidrug/chemical probeClinical trials for CRCResultsZ-scoreP value
Histone deacetylation (Zinc-dependent)
Acide valproïque1I to IIIn combination: OR in 64% patients or SD[76,77]
Belinostat2, Apicidin3
EntinostatI to I/IINo OR[78] or SD[79]
PanobinostatIPR and SD in combination with Bevacizumab[80]
Vorinostat (SAHA)I to IINo OR[81,82]; SD and PR with Bortezomib or 5FU and leucovorin or Doxorubicin[83-85]
Trichostatine A2
Mocetinostat2
Sodium phenylbutyrate2IIn combination with 5-FU: SD[86]
Class IRomidepsin (Istodax)1IIIneffective[86]
CI-994IPR in combination with carboplatin and placlitaxel[87]
HDAC8TM-2-514, CUDC-1012, Pracinostat2, Ricolinostat2, Citarinostat2, Abexinostat2, Quisinostat3, PCI-340513-2.5270.0115
Class IIa (1 catalytic site, mainly cytoplasmic)
HDAC5CUDC-1012, Pracinostat2, Domatinostat2, Quisinostat3, LMK-2353, TMP1953, TMP2693-4.1333.581E-05
Class IIb (2 catalytic sites, mainly cytoplasmic)
HDAC10CUDC-1012, CUDC-9072, Pracinostat2, Domatinostat2, Abexinostat2, Tucidinostat2, Quisinostat3-3.170.001525
Histone deacetylation NAD+ dependent (Class III)
Resveratrol4IReduced cell proliferation[88]
Salermide3[89]
SIRT6OSS_1281673-3.4670.0005257
SIRT7-2.5820.009835
Histone demethylation
LSD family of demethylases
ORY-10013, (±)-tranylcypromine3
KDM2B--3.540.0004003
KDM4D--2.7040.006848
JmjC containing lysine demethylases
JIB-043
JMJD6IOX13-2.590.00961
JMJD5IOX13-2.5880.009654
1Approved for the treatment of other diseases;
2Used in clinical trials for other diseases;
3Not yet used in clinical trials;
4Activator. CRC: Colorectal cancer; OR: Objective response; SD: Stable disease; PR: Partial response.
Full Size Table
Table 3 Positive correlation between combined expression of cancer stem cell markers CD133, CD44 and CD166 and epigenetic erasers
Family/gene symbolPutative epidrug/chemical probeZ-scoreP value
DNA demethylation
TET2-5.9682.40E-09
Histone demethylation
LSD family of demethylases
ORY-10013, (±)-tranylcypromine3
KDM3B5.6361.74E-08
KDM4BCP23[90]5.2121.87E-07
KDM4CCP23[90]3.8959.81E-05
KDM5BCPI-4553, AS-83513, 593 (KDOAMA-253)[90]9.0929.72E-20
KDM6AGSK-J132.840.00451
KDM6BGSK-J134.0145.98E-05
1Approved for the treatment of other diseases; 2Used in clinical trials for other diseases;
3Not yet used in clinical trials.
Full Size Table
Table 4 Positive correlation between combined expression of cancer stem cell markers CD133, CD44 and CD166 and epigenetic writers
Family/gene symbolEpidrug/chemical probeClinical trials for CRCResults/statusZ-scoreP value
Histone acetyltransferases
EP300CurcuminEarly phase I to IIILow bioavailability[91]2.5130.01198
Garcinol3, C6463
NCOA1Bufalin2[92]5.455.04E-08
NCOA4-4.1832.88E-05
NCOA7-5.7887.14E-09
KAT2BIschemin3[93]6.5147.31E-11
Activating Lysine methyltransferases
ASH1L-2.5910.009565
SMYD1-2.7390.00616
SETD7PFI-235.113.23E-07
Repressing Lysine methyltransferases
PRDM8-3.4110.0006465
Putative Lysine methyltransferase
PRDM10-2.4480.01438
Arginine methyltransferases
PRDM1-2.8740.004056
PRMT2-2.9010.003726
Histone ubiquitination
UBE2B-2.7480.005991
UBE2H-5.8096.30E-09
Histone phosphorylation
JAK1RuxolitinibPhase I and IINo benefit over Regorafenib alone[94]7.7391.01E-14
Baricitinib2, Momelotinib2, Filgotinib2, Decernotinib2, Cerdulatinib2, Solcitinib2, Oclacitinib maleate2
JAK2RuxolitinibPhase I and IINo benefit over Regorafenib alone[94]6.72.09E-11
Gandotinib2, AZD14802, BMS-9115432, AT92832, XL0192, Baricitinib2, Momelotinib2, Filgotinib2, Decernotinib2, Cerdulatinib2, JAK2/HDAC Dual Inhibitors3[95]
Histone biotinylation
BTDBiotinyl-methyl 4-(amidomethyl)benzoate3[96]4.3791.19E-05
1Approved for the treatment of other diseases;
2Used in clinical trials for other diseases;
3Not yet used in clinical trials. CRC: Colorectal cancer.
Full Size Table
Table 5 Positive correlation between combined expression of cancer stem cell markers CD133, CD44 and CD166 and epigenetic readers
Family/gene symbolEpidrug/chemical probeZ-scoreP value
Methylated DNA binding
MBD1-2.5930.009517
MBD2-3.4770.0005076
ZBTB4-5.4963.89E-08
Methylated histone binders
Zinc finger, PHD-type
DPF33.5030.0004602
BromodomainApabetalone2, Bromosporine3
BPTF2.6210.008773
BAZ2BGSK280134.7911.66E-06
Tudor domain
TDRD1-2.4590.01394
TP53BP1-2.9650.003029
Other cofactors of epigenetic complexes
RBBP5-2.9660.003014
TADA2B-3.3820.0007189
ELP2PLX-472033.2770.00105
ELP3-2.6220.00875
TAB2-2.5510.01074
NCOR1-3.620.0002949
Chromodomain (Chromatin Organization Modifier Domain)
CHD1, CHD3, CHD9-3.007/4.099/4.367< 0.003
1Approved for the treatment of other diseases;
2Used in clinical trials for other diseases;
3Not yet used in clinical trials.
Full Size Table
Table 6 Negative correlation between combined expression of cancer stem cell markers CD133, CD44 and CD166 and epigenetic readers
Family/gene symbolPutative epidrug/chemical probeZ-scoreP value
Methylated DNA binding
MBD3--3.6010.0003174
ZBTB38 (Kaiso family)--2.5570.01055
Histone binders
Bromodomains
BRD7BI72733, BI-95643, TP-4723[97]-4.9069.301E-07
Zinc finger, Plant Homeodomain (PHD)-type
ING1, ING5--2.544/-4.255< 0.05
PHF20--3.0940.001973
PHF14--2.9340.003344
PHF5A--2.5210.01171
DPF1--2.780.00543
Tudor domain
TDRKH--2.7550.005875
WD40 motif
EEDA-3953[98]-4.3071.652E-05
Other cofactors of epigenetic complexes
DPY30--3.5490.0003863
WDR5OICR-94293-3.310.0009321
TADA2A-2.4730.01341
1Approved for the treatment of other diseases; 2Used in clinical trials for other diseases;
3Not yet used in clinical trials.
Full Size Table
Write to the Help Desk
© 2004-2025 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

California Corporate Number: 3537345